Caribou Biosciences, Inc.

NASDAQ:CRBU

Biotechnology

Healthcare
$0.49 -2.74%

-$0.05 today

Market cap
$52.47M
Beta
2.33
P/E (TTM)
-1.1
EPS (TTM)
-$1.39
52W Low $1.20High $3.54

Volume 1.01M

Average 1.83M

CRBU Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Caribou Biosciences, Inc.NASDAQ: CRBU

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables falls 13.8% from a year ago

Net receivables stood at $2.36M at the end of Q1 FY2026, down 13.8% from a year earlier and down 20.7% from the prior quarter. Over 3 fiscal years it compounded at -13.9% a year.

Context

  • Net receivables amounted to 1.6% of total assets at the end of Q1 FY2026, up 0.6 pp from a year earlier.
  • Net receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps falling in the next quarterly balance sheet after a -13.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.36M-20.7% QoQ
Last fiscal yearDec 2025
$2.98M-8.4% YoY
Year agoMar 2025
$2.74M-13.8% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-13.8%——
1 year-8.4%——
3-year CAGR-13.9%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
2.98M USD
Year-over-year change
-8.4%
4-year CAGR
-22.2%

Net Receivables vs competitors

How CRBU compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -13.8% is the 3rd highest of 5, against a peer median of -18.0%.
  • Net receivables amounts to 1.6% of total assets for CRBU, versus a peer median of 0.2%.
CRBU Competitors
Net Receivables for CRBU and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TNYATenaya Therapeutics, Inc.Mar 2026$10.63M USD——7.9%
IVAInventiva S.A.Dec 2025€9.12M EUR-25.0%+219.7%3.7%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$7.83M USD-80.7%-48.0%2.5%
CRBUCaribou Biosciences, Inc.Mar 2026$2.36M USD-13.8%-13.9%1.6%
ALLOAllogene Therapeutics, Inc.Mar 2026$1.3M USD——0.3%
HUMAHumacyte, Inc.Mar 2026$434K USD-11.1%+142.3%0.4%
OBIOOrchestra BioMed Holdings, Inc.Mar 2026$84K USD-5.6%-0.3%0.1%
PRLDPrelude Therapeutics IncorporatedMar 2026$0 USD——0.0%
FHTXFoghorn Therapeutics Inc.Mar 2026$0 USD——0.0%
PYXSPyxis Oncology, Inc.Mar 2026$0 USD—+5.4%0.0%
AARDAardvark Therapeutics, Inc. Common StockMar 2026$0 USD——0.0%
Peer median (excluding CRBU) —-18.0%+5.4%0.2%

Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents240.42M58.34M51.16M16.29M12.36M
Short-term Investments135.41M189.33M277.67M193.24M126.98M
Net Receivables8.12M4.66M3.86M3.25M2.98M
Inventory00000
Other Current Assets671K1.12M1.22M1.78M2.91M
Total Current Assets391.19M260.25M338.84M219.38M145.23M
Property, Plant & Equipment (Net)4.89M34.91M40.45M39.29M24.43M
Goodwill00000
Intangible Assets00000
Long-term Investments45.3M77.07M51.33M49.13M3.55M
Tax Assets00000
Other Non-current Assets975K1.54M1.59M5.52M2.15M
Total Non-current Assets51.16M113.52M93.37M93.94M30.14M
Total Assets442.36M373.77M432.21M313.31M175.37M
Account Payables3.99M1.15M3.12M2.48M5.78M
Short-term Debt259K0000
Tax Payables00000
Deferred Revenue8.7M9.94M2.85M3.13M1.9M
Other Current Liabilities4.75M7.12M10.62M10.22M8.56M
Total Current Liabilities25.83M28.13M28.3M30.65M25.41M
Long-term Debt00000
Deferred Tax Liabilities476K381K557K548K4.27M
Deferred Revenue (Non-current)22.03M15.95M6.1M3.32M1.75M
Other Non-current Liabilities6.19M1.65M2.94M785K(4.27M)
Total Non-current Liabilities28.7M44.77M35.51M29.71M27.78M
Total Liabilities54.53M72.89M63.81M60.36M53.19M
Common Stock6K6K8K9K9K
Retained Earnings(97.79M)(197.22M)(299.29M)(448.39M)(596.52M)
Accumulated OCI(135K)(1.52M)30K255K103K
Other Stockholders Equity00000
Minority Interest00000
Total Equity387.83M300.87M368.4M252.95M122.18M
Total Debt259K27.75M27.11M26.49M27.23M
Net Debt(240.42M)(30.59M)(24.05M)10.19M14.87M

Caribou Biosciences, Inc.

NASDAQ:CRBU

Intrinsic Alpha fair value

Locked

Current Price

$0.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.